Related references
Note: Only part of the references are listed.Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: The contribution of expectation
Antonio P. Strafella et al.
NEUROIMAGE (2006)
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
F Gardoni et al.
JOURNAL OF NEUROSCIENCE (2006)
Nondopaminergic mechanisms in levodopa-induced dyskinesia
JA Brotchie
MOVEMENT DISORDERS (2005)
Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz et al.
MOVEMENT DISORDERS (2005)
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)
CW Olanow et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus
F Benedetti et al.
NATURE NEUROSCIENCE (2004)
The placebo effect in neurological disorders
R de la Fuente-Fernández et al.
LANCET NEUROLOGY (2002)
Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
CG Goetz et al.
MOVEMENT DISORDERS (2002)
Expectation and dopamine release:: Mechanism of the placebo effect in Parkinson's disease
R de la Fuente-Fernández et al.
SCIENCE (2001)
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
E Bezard et al.
NATURE REVIEWS NEUROSCIENCE (2001)
Share Paper
